相关实验视频

Updated: Jan 6, 2026

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

Published on: June 19, 2025

通过超声波和向alpha (v) -integrins的微泡来进行血管生成的非侵入性评估

Howard Leong-Poi¹, Jonathan Christiansen, Alexander L Klibanov

¹Cardiovascular Imaging Center, Cardiovascular Division, University of Virginia, Charlottesville 22908, USA.

|January 29, 2003

概括

使用向微气泡的对比增强超声波 (CEU) 可以非侵入性地绘制新的血管形成图像. 这种方法有望通过可视化表达alpha(v) -integrins的新血管来评估治疗性血管生成.

科学领域:

生物医学成像技术生物医学成像技术
血管生物学血管生物学
超声波技术超声波技术超声波技术

背景情况:

缺乏非侵入性方法来表征血管生成期间的新血管形成.
血管新生对于各种生理和病理过程至关重要.
有针对性的分子成像为改善诊断能力提供了潜力.

研究的目的:

开发和评估对比增强超声波 (CEU),使用向α-v-整合素的微泡,用于成像血管生成.
评估目标微气泡在新血管中的保留和结合.
确定CEU是否可以在体内量化新血管形成.

主要方法:

准备针对alpha(v) -integrins的微泡,使用埃希斯塔丁 (MB(E)) 或抗alpha(v) 抗体 (MB(alpha)).
在小鼠的cremaster肌肉中评估微泡的行为,使用静脉内显微镜.
在使用CEU的FGF-2诱导的母体塞中新血管化的体内成像.

主要成果:

与对照微气泡 (MB(c)) 相比,向微气泡 (MB(E) 和MB(alpha)) 的微血管保留显著更大.
保留的向微泡附着在微血管内皮表面.
针对性微气泡的CEU显示了更高的声学强度,与新血管血量有很好的相关性.

结论:

使用alpha (v) -integrin向微泡的CEU是一种可行的非侵入性方法,用于成像血管生成.
这种方法可以使治疗性血管生成的评估.
该技术提供了对新血管化的定量测量.

更多相关视频

Cancer Vaccines

Cancer Vaccines

Development of Immunocompetence

Development of Immunocompetence

相关概念视频

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Vaccinations

Vaccinations

Healthcare Associated Infections II: Preventive Measures

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...